Amgen (AMGN) Other financing activities (2009 - 2026)

Amgen has reported Other financing activities for 18 years, with the latest figure at -$120.0 million in Q2 2026.

• On a quarterly basis, Other financing activities fell 30.43% year-over-year to -$120.0 million in Q2 2026; TTM through Jun 2026 was -$157.0 million, a 38.94% decrease from a year earlier, with the FY2025 full-year figure at -$52.0 million, up 58.06% from the prior year.
• Other financing activities was -$120.0 million for Q2 2026 at Amgen, down from -$104.0 million in the prior quarter.
• The five-year high for Other financing activities was $57.0 million in Q4 2025, with the low at -$120.0 million in Q2 2026.
• Average Other financing activities over 5 years is -$31.9 million, with a median of -$26.5 million recorded in 2022.
• The sharpest annual moves came in 2025 and 2026: Other financing activities soared 2950.0% in 2025, then slumped 285.19% in 2026.
• Over 5 years, Other financing activities stood at $10.0 million in 2022, then slumped by 150.0% to -$5.0 million in 2023, then surged by 60.0% to -$2.0 million in 2024, then jumped by 2950.0% to $57.0 million in 2025, then sank by 310.53% to -$120.0 million in 2026.
• The last three Other financing activities figures came in at -$120.0 million (Q2 2026), -$104.0 million (Q1 2026), and $57.0 million (Q4 2025), per Business Quant data.